

The interaction of anticancer therapies with tumor-associated macrophages

Alberto Mantovani and Paola Allavena

A. Mantovani and P. Allavena are at the IRCCS Humanitas Clinical and Research Center and Humanitas University, 20089 Rozzano, Milano, Italy

Macrophages are essential components of the inflammatory microenvironment of tumors. Conventional treatment modalities (chemotherapy and radiotherapy), targeted drugs, antiangiogenic agents, and immunotherapy, including checkpoint blockade, all profoundly influence or depend on the function of tumor-associated macrophages (TAMs). Chemotherapy and radiotherapy can have dual influences on TAMs in that a misdirected macrophage-orchestrated tissue repair response can result in chemoresistance, but in other circumstances, TAMs are essential for effective therapy. A better understanding of the interaction of anticancer therapies with innate immunity, and TAMs in particular, may pave the way to better patient selection and innovative combinations of conventional approaches with immunotherapy.

CORRESPONDENCE

Alberto Mantovani:
alberto.mantovani@
humanitasresearch.it
OR

Paola Allavena:
paola.allavena@
humanitasresearch.it

Inflammatory cells and mediators are an essential constituent of the tumor microenvironment (Mantovani et al., 2008; Hanahan and Weinberg, 2011; Coussens et al., 2013). Cells of the monocyte-macrophage lineage are major components of the host cell infiltrate of tumors, and the analysis of their function has led to the dissection of tumor-promoting inflammatory mechanisms in cancer (Mantovani et al., 1992; Sica and Mantovani, 2012; De Palma and Lewis, 2013; Noy and Pollard, 2014). In primary tumors and in metastatic sites, tumor-associated macrophages (TAMs) engage in complex bidirectional interactions with tumor cells, cancer stem cells (CSCs), fibroblasts, mesenchymal stem cells, endothelial cells, and T, B, and NK cells.

Although macrophages have the potential to kill tumor cells and to elicit tumor-destructive reactions, several lines of evidence indicate that TAMs are drivers of tumor progression in established tumors, promoting cancer cell proliferation and survival, angiogenesis, and lymphangiogenesis and skewing and taming effective T cell responses. There is also evidence that chronic inflammatory circuits may mediate tumor initiation and promote genetic instability (Mantovani et al., 2008; Noy and Pollard, 2014).

TAM infiltration in the face of a growing tumor is thought to be maintained by monocyte recruitment and differentiation (Mantovani et al., 1992). The discovery that most mouse

tissue macrophages derive from the yolk sac or embryonic hematopoietic stem cells and self-maintain independently of adult bone marrow (Wynn et al., 2013), as well as the importance of macrophage proliferation in certain inflammatory disorders (e.g., Jenkins et al., 2011), called for a reexamination of the origin of TAMs and of the mechanisms that sustain their numbers. In some mouse tumors, local proliferation does occur (Bottazzi et al., 1990; Tymoszyk et al., 2014), but recent evidence suggests that, in general, recruitment of circulating monocytes is essential for TAM accumulation (Franklin et al., 2014; Noy and Pollard, 2014; Shand et al., 2014). Chemokines (e.g., CCL2), cytokines (e.g., colony-stimulating factor-1 [CSF-1]), and products of the complement cascade (Bonavita et al., 2015) are major determinants of macrophage recruitment and positioning in tumors (Noy and Pollard, 2014).

Plasticity and diversity are hallmarks of cells of the monocyte-macrophage lineage (Fig. 1; Mosser and Edwards, 2008; Biswas and Mantovani, 2010; Sica and Mantovani, 2012). Two monocyte subsets have been identified, inflammatory monocytes (CCR2^{high}Ly6C⁺ in mouse; CCR2^{high}CD14^{high}CD16⁻ in human)

© 2015 Mantovani and Allavena. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at <http://creativecommons.org/licenses/by-nc-sa/3.0/>).




Figure 1. A snapshot of monocyte and macrophage diversity. Two main phenotypically distinct subsets can be identified in the blood: inflammatory monocytes (CCR2⁺Ly6C⁺ in mice; CCR2⁺CD14⁺CD16⁻ in humans) and patrolling monocytes (CX3CR1⁺ in mice; CX3CR1⁺CD14^{+/-}CD16⁺ in humans). In tissues, macrophages in different organs have different morphological and functional features (e.g., peritoneal macrophages, alveolar macrophages, and liver Kupffer cells). Upon activation with specific signal, macrophages initiate functional programs that are dictated by transcription factors (in rectangles). Two main functional polarizations can be distinguished: classical or M1 and alternative or M2. Other signals, including immune complexes in conjunction with LPS or IL-1, and immune-suppressive cytokines, including IL-10 and TGFβ, also turn on macrophages along an M2-like polarization.

and patrolling monocytes (CX3CR1^{high}Ly6C⁻ in mouse; CX3CR1^{high}CD14^{dim}CD16⁺ in human). The CCR2–CCL2 pathway is an important determinant of monocyte recruitment and functional orientation of monocytes in tumors. It is not yet clear whether patrolling monocytes, which survey the intravascular space, have a specific function in the development of cancer.

Under homeostatic conditions, macrophages located in different tissues originate from embryonic precursors and acquire distinct morphological and functional features (Fig. 1), with the exception of the adult hematopoietic origin of gut, heart, and dermis macrophages (Bain et al., 2014; McGovern et al., 2014; Molawi et al., 2014). The recent identification of key transcription factors involved in the differentiation of tissue macrophages, such as GATA6 for peritoneal cells (Gautier et al., 2014; Okabe and Medzhitov, 2014; Rosas et al., 2014) and SPI-C for red pulp macrophages (Kohyama et al., 2009), and an increased understanding of the epigenetic landscape of resting and activated macrophages (De Santa et al., 2007; Ostuni et al., 2013; Gosselin et al., 2014; Lavin et al., 2014) will likely pave the way to an increased understanding of macrophage diversity in tissues under resting and inflammatory conditions.

Monocytes and macrophages undergo profound functional reprogramming (“activation”) in response to microbial signals, tissue damage, cytokines, and metabolic products, the diverse outcomes of which reflect the extreme plasticity of mononuclear phagocytes (Mosser and Edwards, 2008; Sica and Mantovani, 2012; Murray et al., 2014). The nomenclature used to define macrophage functional plasticity in response to environmental signals has been the object of some debate. A recent consensus study (Murray et al., 2014) emphasized the extreme plasticity of cells of the monocyte-macrophage lineage, as well as the need to carefully define experimental conditions and to avoid confusion deriving from the use of the same terms to refer to cells exposed to different signals. The consensus view is that the terms M1 and M2, which mirror Th1/Th2 or ILC1/ILC2 and are synonymous with “classical” and “alternative” cell types, should be confined to activated cells driven by IFNγ with LPS and IL-4 or IL-13 and avoided, for instance, for GM-CSF- and M-CSF-stimulated cells.

M1- and M2-polarized macrophages are extremes of a continuum (Fig. 1) in a universe of functional states. M1- and M2-polarized macrophages differ in many aspects, including the cytokine (e.g., IL-12^{high}IL-10^{low} vs. IL-12^{low}IL-10^{high})




Figure 2. Schematic representation of cells and mediators influencing the function of TAMs. On the left side, different cells belonging to the immunological network, as well as tumor cells and tumor-associated fibroblasts, all may influence the functional conditioning of TAMs by producing specific soluble mediators such as cytokines, chemokines, and growth factors. For instance, Th2 cytokines (IL-4/IL-13) and other cytokines such as IL-10 and TGF β , metabolic products derived by tumor cells (lactic acid) and immune complexes, drive TAM polarization into tumor-promoting macrophages. On the right side are listed the major protumor functions of TAMs. For instance, by producing survival factors (IL-6 and MFG-E8) and osteopontin, TAMs protect CSCs from the toxic effect of chemotherapy or directly stimulate tumor cell proliferation via epidermal growth factor (EGF). TAM production of nitric oxide (NO) and reactive oxygen species (ROI) induces genetic instability. TAMs switch on neoangiogenesis by secreting VEGF and suppress immune responses because they express inhibitory molecules (PD-L1 and B7-4) and produce immunosuppressive cytokines/mediators (IL-10 and arginase). In the rectangle, selected transcription factors that orchestrate TAM function are highlighted.

and chemokine repertoire (e.g., CXCL9 and CXCL10 for M1, CCL17 and CCL22 for M2), iron, glucose, and folate metabolism, and scavenger and mannose receptors. In general, M1-polarized macrophages mediate resistance to intracellular pathogens and tumors in the context of Th1-driven responses, whereas M2-polarized macrophages mediate resistance to parasites, immunoregulation, and tissue repair and remodeling. Transcription factors involved in M1 polarization include NF- κ B, STAT1, and IRF5 (Krausgruber et al., 2011), whereas IRF4, STAT6, MYC, and, secondarily, PPAR γ and KLF4 have been associated with M2 polarization (Sica and Mantovani, 2012; Murray et al., 2014). Various signals regulate macrophage function, including CSFs, immune complexes with or without IL-1 or LPS, TGF β , IL-10, and chemokines.


Signals derived from tumor and host cells shape the functional phenotype of TAMs. In different tumor and tissue contexts, these functional determinants include hypoxia, cytokines (e.g., TGF β and CSF-1), and metabolic products of cancer cells (e.g., lactic acid), IL-4 and IL-13 produced by Th2 cells (which drive development of M2 cells in the strictest sense), IL-10 produced by T reg cells, and B cells and immune complexes (Fig. 2; Mantovani et al., 2008; Ruffell et al., 2012; Sica and Mantovani, 2012; Coussens et al., 2013; De Palma and Lewis, 2013; Colegio et al., 2014; Noy and Pollard, 2014). Within the cancer tissue, there can be micro-anatomical diversity of TAM function with accumulation of cells with protumor properties in hypoxic areas (Movahedi et al., 2010). Moreover, inflammatory components and pathways differ in tumors originating in distinct anatomical sites (Ruffell et al., 2012).

The evidence and consensus about the role of TAMs in tumor-promoting inflammation (Hanahan and Weinberg, 2011) raise the issue of their involvement in current treatment modalities and of their potential as therapeutic targets. Here, we review the impact and significance of the interactions between cells of the monocyte-macrophage lineage and different therapeutic approaches, ranging from conventional chemotherapy to immunotherapy checkpoint blockade, and the ongoing development of macrophage-targeting strategies.

The yin-yang of cancer therapies

Cancer cell-centered therapeutic strategies and immunotherapy profoundly influence the function of TAMs by directly modulating their activity or by affecting components of the tumor microenvironment (e.g., effective adaptive immune responses). During cancer therapy, TAMs can have a yin-yang function in that they either contribute to the ultimate efficacy of anticancer strategies or have a tumor-promoting function by orchestrating a misdirected tissue repair response, as we discuss below for different therapeutic strategies.

Chemotherapy. Conventional chemotherapeutic agents can inhibit or activate effective antitumor responses, including those mediated by cells of the monocyte-macrophage lineage (Fig. 3). Immunity can contribute to the antineoplastic efficacy of selected chemotherapeutic agents (e.g., cyclophosphamide and doxorubicin; Mantovani et al., 1979), but the underlying mechanisms have remained elusive. It is conceivable that chemotherapeutic agents elicit a misdirected macrophage-orchestrated tissue repair response by causing tissue damage in the tumor (Mantovani et al., 2013), which may



Mechanism limiting therapy response	Example agent	Mechanism contributing to therapy response	Example agent
Misguided tissue repair	Doxorubicin		
Protumor skewing (M2-like polarization)	Platinum	Myeloid cell recruitment, differentiation into APCs and activation of immune responses	Doxorubicin
Increased CSF-1 and CCL2 production, protumor skewing (M2-like polarization), suppression of CD8+ antitumor responses	Paclitaxel	Immunogenic tumor cell death	Doxorubicin
Skewing of adaptive immunity (tumor-promoting Th17 responses)	Gemcitabine 5-FU	Antitumor M1-like macrophage polarization	CpG Anti-CSF1R
Chemoprotection of cancer stem cells by macrophages		MSDC depletion	Doxorubicin Gemcitabine
		Reduced TAM numbers	Trabectedin Anti-CSF1 Anti-chemokine e.g. anti-CCL2
		ADCC against tumor cells or T reg cells	Anti-CD20 Anti-CTLA4

Figure 3. Dual role of macrophages in the response to selected therapeutic approaches. Macrophages can either limit (–) the antineoplastic efficacy of selected chemotherapeutic agents or contribute (+) to therapy responses. The general context, including tumor immunogenicity, tissue of origin, and microbial conditioning, defines the set point of balance. The left side of the table lists examples of myelomonocytic cells limiting the efficacy of anticancer therapies. The right side of the table lists examples in which myelomonocytic cells contribute to the efficacy of therapy.

result in promotion of tumor growth and limitation of anti-neoplastic efficacy. In vitro and/or in vivo evidence for a tumor-protective function of macrophages is available for some antitumor agents and tumor types (Table 1), including doxorubicin (earlier called Adriamycin), platinum compounds, 5-fluorouracil (5-FU), gemcitabine, paclitaxel (PTX), and combinations of cyclophosphamide, methotrexate, and 5-FU (e.g., Paulus et al., 2006; DeNardo et al., 2011; Shree et al., 2011; Dijkgraaf et al., 2013; Affara et al., 2014). The pathways responsible for the tumor-promoting function of TAMs after chemotherapy are diverse. In different settings, these include increased recruitment of immunosuppressive TAMs by CSF-1 (DeNardo et al., 2011), protumor polarization (Dijkgraaf et al., 2013; Pyonteck et al., 2013), activation via IL-1 of a tumor-promoting Th17 response (Bruchard et al., 2013), and protection against chemotherapy toxicity of CSCs (Jinushi et al., 2011; Mitchem et al., 2013).

These results suggest that in many instances chemotherapy is self-defeating by eliciting a misdirected tissue repair response orchestrated by TAMs. In apparent contrast with these results, immune responses are also essential for the optimal antitumor activity of some drugs (Fig. 3). Selected chemotherapeutic agents, doxorubicin in particular, cause immunogenic cell death of tumor cells, which leads to activation of effective adaptive responses (Kroemer et al., 2013). Myeloid-derived suppressor cells (MDSCs) are operationally defined as an immature heterogeneous population including cells belonging to

the monocytic and neutrophil lineage (Gabrilovich et al., 2012). In a model of mammary carcinoma, doxorubicin was found to reduce the number of MDSCs and to pave the way to effective adoptive T cell transfer (Alizadeh et al., 2014). Doxorubicin-damaged cancer cells released ATP, which caused myeloid cell recruitment and differentiation into antigen-presenting cells, ultimately resulting in effective antitumor adaptive immunity (Ma et al., 2013). Cyclophosphamide-treated leukemic cells released activating cytokines (CCL4, CXCL8, vascular endothelial growth factor [VEGF], and TNF), which recruited monocytes/macrophages and enhanced their phagocytic activity. Co-administration of cyclophosphamide and a therapeutic antibody against B cell leukemia synergistically collaborated to induce tumor cell death and disposal by activated macrophages (Pallasch et al., 2014).

In the mouse, functional conditioning by the microbiome has emerged as a key component shaping the function of myeloid cells in tumors and their role in response to chemotherapy (platinum and cyclophosphamide; Iida et al., 2013; Viaud et al., 2013). In particular, microbial education of myelomonocytic cells is essential to prime for the antitumor activity of platinum combined with CpG (Fig. 3; Iida et al., 2013).

Thus, chemotherapeutic agents engage in a complex interaction with cells of the monocyte-macrophage lineage. Different contexts, including microbial education of innate immunity, the presence of potentially effective adaptive responses, and

Table 1. Pathways responsible for the tumor-protective function of TAMs against chemotherapy

Tumor	Drug	Mechanism	Reference
Mammary, carcinoma	PTX	CSF1-dependent increased recruitment of TAMs	DeNardo et al., 2011
Mammary, carcinoma	PTX, doxorubicin, etoposide	Increased protease activity	Shree et al., 2011
Cervical, carcinoma	Platinum	Protumor polarization of TAMs	Dijkgraaf et al., 2013
EL-4 lymphoma and other transplanted solid tumors	Gemcitabine + 5-FU	Skewed Th17 response	Bruchard et al., 2013
Pancreatic, carcinoma	Gemcitabine	Induction of drug-metabolizing enzyme	Weizman et al., 2014
Lung, colon, pancreas	Various	Protection of CSCs against toxicity	Jinushi et al., 2011; Mitchem et al., 2013

inherent characteristics of different drugs, dictate the outcome of this yin-yang interaction (Fig. 3). The identification of the pathways responsible for the protumor function of TAMs in well-controlled tumor models (e.g., DeNardo et al., 2011; Germano et al., 2013; Pyonteck et al., 2013) has paved the way to clinical evaluation of therapeutic approaches that combine chemotherapy with macrophage-blocking strategies.

Targeted therapies. In spite of their specificity for cancer-associated molecular targets, targeted therapies can influence immune responses, and this interplay can in turn influence their antineoplastic effectiveness. Imatinib is a prototype for molecularly targeted drugs, but has a profound influence on immune responses. In KIT⁺ gastrointestinal stromal tumors (GISTs), TAMs were reported to have a skewed antitumor M1-like phenotype, unlike those present in most cancers (Cavnar et al., 2013). In a mouse model of GIST, imatinib caused a reduction of TAMs via CSF1R-CSF1 inhibition and converted TAMs to an M2-like phenotype via up-regulation of C/EBP β in response to drug-induced apoptotic tumor cells. These cells had no appreciable impact on tumor growth. The same effect was observed in a cohort of GIST patients, and development of resistance was associated with reversal of the phenotype. The relevance of these findings to other tumors that respond to imatinib remains to be established.

Myeloid cells, in particular TIE2-expressing monocytes (TEMs; for review see De Palma and Lewis [2013]), have the potential to promote angiogenesis through multiple pathways. Sorafenib is an inhibitor of several receptor kinases, including VEGFR2, and is active against hepatocellular carcinoma (HCC). In HCC xenografts, sorafenib increased TAM infiltration via induction of CXCL12. Depletion of TAMs potentiated the inhibitory activity of sorafenib on angiogenesis, primary tumor growth, and metastasis (Zhang et al., 2010). In mouse models of HCC, sorafenib was found to revert the polarization of TAMs and to promote their stimulatory activity on NK cells (Sprinzl et al., 2013). Thus, although the available information is still fragmentary, the possible involvement of TAMs as orchestrators of a misdirected tissue repair response or as direct targets should be considered in the assessment and monitoring of targeted therapies.

Antiangiogenesis. The capacity to elicit new vessel formation is a fundamental property of cancer cells, resulting in an

abnormal vascular bed with hypoxic and normoxic microdomains (Hanahan and Weinberg, 2011). TAMs have proangiogenic activity, and macrophage infiltration in tumors is generally associated with high vascular density (Coffelt et al., 2010).

Antiangiogenic therapies based on inhibitors of the VEGF pathway frequently induce transitory responses in patients. In mouse tumor models and in cancer patients, refractoriness to antiangiogenic therapies is associated with higher numbers of CD11b⁺ cells or TEMs infiltrating tumor tissues (Mazzeri et al., 2011; Lu-Emerson et al., 2013; Gabrusiewicz et al., 2014). Destruction of the vessel network caused by antiangiogenic treatments creates a strongly hypoxic microenvironment, up-regulation of HIF1/2 signaling, and, as a compensatory mechanism, an increase in myeloid cell recruitment. Alternative vascular growth factors, other than VEGF, are essential for tumor recurrence, and CD11b⁺Gr1⁺ myeloid cells produce the proangiogenic factor Bv8 (prokineticin-1; Chung et al., 2010). In preclinical models, depletion of TAMs, either by clodronate-loaded liposomes or CSF-1R inhibition, increased the antitumor effects of VEGF-targeted therapies (Zeisberger et al., 2006; Priceman et al., 2010). These data provide a rationale for combining antiangiogenic drugs with macrophage-targeting strategies. Furthermore, disruption of the angiopoietin-2-TIE2 axis (Mazzeri et al., 2011) is a promising approach to complement chemotherapy. Combining antiangiopoietin-2 with low-dose metronomic chemotherapy effectively inhibited the repopulation of myeloid cell and blocked metastatic growth in mice (Srivastava et al., 2014).

Radiotherapy. After irradiation, an influx of myeloid cells occurs with release of inflammatory cytokines (e.g., IL-1) and profibrotic immunosuppressive mediators (TGF β). Recruitment of macrophages ultimately leads to tumor recurrence (Moeller et al., 2004; Shiao and Coussens, 2010; Moding et al., 2013; Russell and Brown, 2013; Xu et al., 2013). Thus, as for chemotherapy, a misdirected tissue repair response can promote tumor recurrence and progression. However, recent studies have shown that the efficacy of fractionated radiotherapy may involve the activation of the immune system. When tumor cells undergo immunogenic cell death (Kroemer et al., 2013), the innate immune system is activated to present tumor-released antigens to the adaptive immune system. The pro-immunogenic effects of fractionated irradiation induced objective responses, even in lesions

that were distant from the treated site (abscopal effect; Durante et al., 2013; Golden et al., 2013, 2014). It is notable that local radiation therapy also proved efficacious in patients who previously progressed after anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) treatment (Postow et al., 2012; Grimaldi et al., 2014).

In an interesting twist, neoadjuvant low-dose γ irradiation was found to normalize the tumor vasculature and to enhance recruitment of tumor-specific T cells in various cancer models (Klug et al., 2013). Interestingly, under these conditions, low-dose irradiation skewed macrophage function to an antitumor mode, with production of T cell-attracting chemokines and down-regulation of immunosuppressive and angiogenic mediators. Thus, as discussed below for chemotherapy and antimacrophage strategies (Affara et al., 2014), the interplay between TAMs and adaptive CD8⁺ T cell antitumor responses during low-dose irradiation is a key determinant of therapeutic outcome.

Monoclonal antibodies and immune checkpoint blockade. B cells and antibodies can trigger protumor functions of cells of the monocyte-macrophage lineage (Coussens et al., 2013; Affara et al., 2014). However, monoclonal antibodies directed against tumor antigens (e.g., CD20 and HER-2) represent invaluable targeted therapies in the clinic. TAMs are potent effectors of antibody-dependent cellular cytotoxicity (ADCC) and contribute to the antitumor activity of anticancer monoclonal antibodies such as anti-CD20 and anti-HER-2 (Sliwkowski and Mellman, 2013; Furness et al., 2014).

The intensity and duration of T cell responses are tightly regulated by immune checkpoints, which are essential to prevent autoimmune reactions (Pardoll, 2012). Molecules involved in checkpoint regulation include CTLA-4, programmed death 1 (PD1), T cell immunoglobulin and mucin domain-containing protein-3 (TIM-3), and lymphocyte activation gene (LAG-3), whose expression is high in intratumor lymphocytes. Monoclonal antibodies that interfere with checkpoint blockade can activate effective immune response against selected tumors, and in some patients, these antibodies have shown clinical efficacy (Pardoll, 2012; Makkouk and Weiner, 2015).

The role of myelomonocytic cells in the action of checkpoint blockade monoclonal antibodies may well have been underestimated. Cells of the monocyte-macrophage lineage or lineages, including TAMs, express the ligands for the inhibitory receptor programmed cell death protein-1 (PDL-1 and PDL2) and CTLA-4. Moreover, TAMs from HCC express the B7 family member B7H4 (Kryczek et al., 2006). It remains unclear whether, and to what extent, these inhibitory molecules contribute to the immunosuppressive activity of TAMs.

The mode of action of immune checkpoint blockade is not completely understood. Recent evidence suggests that anti-CTLA-4 antibodies act via Fc γ receptor-expressing macrophages (Selby et al., 2013; Simpson et al., 2013). Evidence in mouse models suggests that elimination of T reg

cells by macrophage-mediated ADCC is an essential component of the therapeutic activity of anti-CTLA-4 (Selby et al., 2013; Simpson et al., 2013). It will be important to assess the clinical significance of these observations from the perspective of identifying patients responsive to immune checkpoint blockade.

Macrophage targeting

Two general strategies have been used to target myelomonocytic cells in tumors: inhibition of recruitment and/or elimination (the latter achieved by direct killing) and reeducation (Fig. 3). The plasticity and flexibility of myelomonocytic cells (Hagemann et al., 2008; Mosser and Edwards, 2008) provides a basis for strategies aimed at “resetting” TAMs in an antitumor mode. Agents in this broad category include the classic Th1 cytokine IFN γ , which early on showed objective responses in minimal residual ovarian cancer (Colombo et al., 1992; Pujade-Lauraine et al., 1996); bacterial products, with intravesical BCG being part of the armamentarium in bladder cancer; TLR agonists (e.g., CpG oligonucleotides, which are undergoing preclinical and clinical evaluation [e.g., Iida et al., 2013]); and antibodies that activate via the CD40 molecule. A fully human CD40 agonist antibody CP-870,893 was administered in combination with gemcitabine chemotherapy to 21 patients with advanced pancreatic cancer, with partial clinical effects (Beatty et al., 2013). In a mouse model of pancreatic cancer, anti-CD40 was found to modify macrophage phenotype with up-regulation of MHC class II and CD86 (Beatty et al., 2011). Similarly, the plasma protein histidine-rich glycoprotein (HRG) was reported to skew TAM polarization into a phenotype with antitumor activity by down-regulation of the placental growth factor (PlGF), a member of the VEGF family. In mice, HRG promoted antitumor immune responses and normalization of the vessel network (Rolny et al., 2011).

Blocking macrophage recruitment and survival has been extensively investigated in preclinical models and is undergoing clinical evaluation. TAMs typically originate from blood monocytes that are continuously recruited from the circulation (Mantovani et al., 1992; Franklin et al., 2014), although a certain degree of self-renewal in some tumors has been reported (Bottazzi et al., 1990; Tymoszuk et al., 2014). Among chemoattractants that regulate the influx of circulating monocytes in tumor tissue, chemokines have been extensively studied, in particular CCL2 (Weitzenfeld and Ben-Baruch, 2014). Antibodies to CCL2 are now being tested in clinical trials. CNTO 888 (carlumab) showed preliminary antitumor activity in advanced cancer patients and was well tolerated (Pienta et al., 2013; Sandhu et al., 2013). Combinations of carlumab with conventional chemotherapy regimens are being studied in clinical trials (Branca et al., 2014). Recent results caution against the possibility that interruption of anti-CCL2 therapy may lead to enhanced metastasis (Bonapace et al., 2014). In a breast cancer model, cessation of anti-CCL2 therapy was associated with monocyte release from the bone marrow, increased mobilization and infiltration of cancer

cells, and angiogenesis driven by IL-6 and VEGF. In addition, recent results suggest that complement components are key players in cancer-related inflammation and orchestrate macrophage recruitment in part via CCL2 (Bonavita et al., 2015). Thus, targeting complement with available tools (e.g., anti-C5a) should be taken into consideration.

TAMs localized in different compartments of the same tumor lesion can have considerably different functional properties (Movahedi et al., 2010), with a protumor phenotype prevailing in avascular areas. Semaphorin 3A (Sema3A), which is induced by hypoxia, interacts with the holoreceptor, including neuropilin1 (Nrp1) and plexin A1/plexin A4, triggering VEGFR1 phosphorylation and macrophage attraction (Casazza et al., 2013; Laoui et al., 2014). Interestingly, at hypoxic sites, Nrp1 was down-regulated and Sema3A delivered a stop and retention signaling via plexin A1/plexin A4, thus sequestering TAMs in hypoxic niches. Genetic inactivation of Nrp1 resulted in enhanced trapping of TAMs in the normoxic part of the tumor, with inhibition of their immunosuppressive and angiogenic activity (Casazza et al., 2013; Laoui et al., 2014). These results suggest that localization of TAMs in normoxic versus hypoxic regions of tumors may be a strategy to inhibit the protumor phenotype.

CSF-1 is abundantly produced by several tumor types and represents a prime target for antimacrophage strategies using antisense oligonucleotides (Aharinejad et al., 2004; Paulus et al., 2006), monoclonal antibodies, or kinase inhibitors. Antagonists of the CSF-1R tyrosine kinase have been developed and tested in preclinical models, including acute myeloid leukemia, melanoma mammary carcinoma, and glioblastoma, with promising results (e.g., Goswami et al., 2005; Manthey et al., 2009; DeNardo et al., 2011; Pyonteck et al., 2013). Interestingly, CSF-1R inhibition in glioblastoma did not reduce TAM numbers but blocked their tumor-promoting functions (Pyonteck et al., 2013). In an important proof-of-principle study, an anti-CSF-1R antibody (RG7155) was recently demonstrated to reduce macrophage infiltration in mouse tumor models and in patients. In patients with a rare sarcoma with high production of CSF1 (diffuse-type giant cell tumor), treatment with this antibody resulted in objective clinical responses (Ries et al., 2014).

As mentioned above, TAMs influence the tumor response to chemotherapy. In a transgenic mouse model of mammary adenocarcinoma, PTX up-regulated CSF-1, IL-34 (a growth factor using the CSF-1 receptor), and CCL8 in tumor cells. Blockade of the CSF1–CSF1R loop, either with anti-CSF1 antibodies or a CSF-1R inhibitor, in combination with chemotherapy, enhanced the therapeutic efficacy, inhibited metastases, and increased the recruitment of CD8 T cells in tumors (DeNardo et al., 2011). A more in-depth, mechanistic analysis of the interplay between TAMs and CD8⁺ T cells in the context of combined therapies revealed a more complex circuit (Ruffell et al., 2014). TAMs were the main source of IL-10, and anti-IL-10R was as effective as anti-CSF1 when combined with PTX and carboplatin. However, perhaps unexpectedly, macrophage-derived IL-10

did not directly affect CD8⁺ T cell function; rather, it inhibited IL-12 expression in intratumor DCs, thus blocking activation of an effective adaptive response (Ruffell et al., 2014). Similar to the approach of targeting macrophages to reactivate T cell effector function, selective expression of an IFN α transgene in monocytes inhibited tumor progression in mammary carcinoma and enhanced cytotoxic T cells (Escobar et al., 2014). It is possible that intratumor DCs also play a role as an intermediary component between TAMs and adaptive immunity. The enhancement of chemotherapeutic responses by macrophage depletion in different settings therefore provides a rationale for clinical testing of combined therapeutic approaches.

It has recently been demonstrated that targeting of TAMs plays a key role in the antitumor activity of a clinically approved drug (Germano et al., 2013). Trabectedin was originally derived from the marine organism *Ecteinascidia turbinata* and is approved in Europe (by the EMEA) for the treatment of sarcomas and ovarian carcinoma. It is selectively cytotoxic for human and mouse monocytes, including TAMs, and induces caspase-dependent apoptosis (Fig. 3; Germano et al., 2013). Evidence in the mouse and in sarcoma patients suggests that macrophage depletion is a key mechanism of action of the antitumor activity of this agent. In biopsies from sarcoma patients treated with trabectedin, a significant decrease of TAMs and vessel networks was noted (Germano et al., 2013). These results provide proof-of-principle for macrophage targeting in human cancer and may have implications for the design of combination therapies.

Concluding remarks

Myelomonocytic cells have emerged as an essential component of tumor-promoting inflammation (Mantovani et al., 1992, 2008; Hanahan and Weinberg, 2011; Coussens et al., 2013; Noy and Pollard, 2014). Evidence suggests that cells of the monocyte-macrophage lineage can have a dramatic impact on the outcome of current treatment modalities. It will be important to definitively assess whether TAMs or TAM-related biomarkers can serve to guide diverse therapeutic approaches, including checkpoint blockade strategies. Development of effective strategies targeting myelomonocytic cells in tumor tissues or reeducating or relocating them will require a better understanding of their molecular pathways and diversity. The identification of genetic and epigenetic mechanisms (e.g., Ostuni et al., 2013; Okabe and Medzhitov, 2014; Rosas et al., 2014) underlying macrophage diversity in tissues and their different forms of activation is likely to pave the way to reeducation strategies. Although these strategies are in their infancy, early clinical trials are ongoing, and there is proof-of-principle that targeting TAMs can be clinically beneficial (Germano et al., 2013; Ries et al., 2014). However, macrophage-targeting strategies are unlikely to be effective per se and will need to be combined with conventional therapeutic approaches, capitalizing on an improved understanding of their interaction with mononuclear phagocytes.

This work was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC; to A. Mantovani and P. Allavena), the Ministero della Salute, and the Ministero dell'Università e Ricerca.

The authors declare no competing financial interests.

Submitted: 30 September 2014

Accepted: 17 February 2015

REFERENCES

- Affara, N.I., B. Ruffell, T.R. Medler, A.J. Gunderson, M. Johansson, S. Bornstein, E. Bergsland, M. Steinhoff, Y. Li, Q. Gong, et al. 2014. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. *Cancer Cell*. 25:809–821. <http://dx.doi.org/10.1016/j.ccr.2014.04.026>
- Aharinejad, S., P. Paulus, M. Sioud, M. Hofmann, K. Zins, R. Schäfer, E.R. Stanley, and D. Abraham. 2004. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. *Cancer Res*. 64:5378–5384. <http://dx.doi.org/10.1158/0008-5472.CAN-04-0961>
- Alizadeh, D., M. Trad, N.T. Hanke, C.B. Larmonier, N. Janikashvili, B. Bonnotte, E. Katsanis, and N. Larmonier. 2014. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. *Cancer Res*. 74:104–118. <http://dx.doi.org/10.1158/0008-5472.CAN-13-1545>
- Bain, C.C., A. Bravo-Blas, C.L. Scott, E. Gomez Perdiguero, F. Geissmann, S. Henri, B. Malissen, L.C. Osborne, D. Artis, and A.M. Mowat. 2014. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. *Nat. Immunol.* 15:929–937. <http://dx.doi.org/10.1038/ni.2967>
- Beatty, G.L., E.G. Chiorean, M.P. Fishman, B. Saboury, U.R. Teitelbaum, W. Sun, R.D. Huhn, W. Song, D. Li, L.L. Sharp, et al. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. *Science*. 331:1612–1616. <http://dx.doi.org/10.1126/science.1198443>
- Beatty, G.L., D.A. Torigian, E.G. Chiorean, B. Saboury, A. Brothers, A. Alavi, A.B. Troxel, W. Sun, U.R. Teitelbaum, R.H. Vonderheide, and P.J. O'Dwyer. 2013. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. *Clin. Cancer Res*. 19:6286–6295. <http://dx.doi.org/10.1158/1078-0432.CCR-13-1320>
- Biswas, S.K., and A. Mantovani. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. *Nat. Immunol.* 11:889–896. <http://dx.doi.org/10.1038/ni.1937>
- Bonapace, L., M.M. Coissieux, J. Wyckoff, K.D. Mertz, Z. Varga, T. Junt, and M. Bentires-Alj. 2014. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. *Nature*. 515:130–133. <http://dx.doi.org/10.1038/nature13862>
- Bonavita, E., S. Gentile, M. Rubino, V. Maina, R. Papait, P. Kunderfranco, C. Greco, F. Feruglio, M. Molgora, I. Laface, et al. 2015. PTX3 acts as an extrinsic oncosuppressor by regulating complement-dependent inflammation in cancer. *Cell*. 160:700–714. <http://dx.doi.org/10.1016/j.cell.2015.01.004>
- Bottazzi, B., E. Erba, N. Nobili, F. Fazioli, A. Rambaldi, and A. Mantovani. 1990. A paracrine circuit in the regulation of the proliferation of macrophages infiltrating murine sarcomas. *J. Immunol.* 144:2409–2412.
- Brana, I., A. Calles, P.M. LoRusso, L.K. Yee, T.A. Puchalski, S. Seetharam, B. Zhong, C.J. de Boer, J. Tabernero, and E. Calvo. 2014. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. *Target Oncol.* <http://dx.doi.org/10.1007/s11523-014-0320-2>
- Bruchard, M., G. Mignot, V. Derangère, F. Chalmin, A. Chevriaux, F. Végran, W. Boireau, B. Simon, B. Ryffel, J.L. Connat, et al. 2013. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. *Nat. Med.* 19:57–64. <http://dx.doi.org/10.1038/nm.2999>
- Casazza, A., D. Laoui, M. Wenes, S. Rizzolio, N. Bassani, M. Mambretti, S. Deschoemaeker, J.A. Van Genderachter, L. Tamagnone, and M. Mazzone. 2013. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. *Cancer Cell*. 24:695–709. <http://dx.doi.org/10.1016/j.ccr.2013.11.007>
- Cavnar, M.J., S. Zeng, T.S. Kim, E.C. Sorenson, L.M. Ocuin, V.P. Balachandran, A.M. Seifert, J.B. Greer, R. Popow, M.H. Crawley, et al. 2013. KIT oncogene inhibition drives intratumoral macrophage M2 polarization. *J. Exp. Med.* 210:2873–2886. <http://dx.doi.org/10.1084/jem.20130875>
- Chung, A.S., J. Lee, and N. Ferrara. 2010. Targeting the tumour vasculature: insights from physiological angiogenesis. *Nat. Rev. Cancer*. 10:505–514. <http://dx.doi.org/10.1038/nrc2868>
- Coffelt, S.B., C.E. Lewis, L. Naldini, J.M. Brown, N. Ferrara, and M. De Palma. 2010. Elusive identities and overlapping phenotypes of pro-angiogenic myeloid cells in tumors. *Am. J. Pathol.* 176:1564–1576. <http://dx.doi.org/10.2353/ajpath.2010.090786>
- Colegio, O.R., N.Q. Chu, A.L. Szabo, T. Chu, A.M. Rheebergen, V. Jairam, N. Cyrus, C.E. Brokowski, S.C. Eisenbarth, G.M. Phillips, et al. 2014. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. *Nature*. 513:559–563. <http://dx.doi.org/10.1038/nature13490>
- Colombo, N., F. Peccatori, C. Paganin, S. Bini, M. Brandely, C. Mangioni, A. Mantovani, and P. Allavena. 1992. Anti-tumor and immunomodulatory activity of intraperitoneal IFN- γ in ovarian carcinoma patients with minimal residual tumor after chemotherapy. *Int. J. Cancer*. 51:42–46. <http://dx.doi.org/10.1002/ijc.2910510109>
- Coussens, L.M., L. Zitvogel, and A.K. Palucka. 2013. Neutralizing tumor-promoting chronic inflammation: a magic bullet? *Science*. 339:286–291. <http://dx.doi.org/10.1126/science.1232227>
- De Palma, M., and C.E. Lewis. 2013. Macrophage regulation of tumor responses to anticancer therapies. *Cancer Cell*. 23:277–286. <http://dx.doi.org/10.1016/j.ccr.2013.02.013>
- De Santa, F., M.G. Totaro, E. Prosperini, S. Notarbartolo, G. Testa, and G. Natoli. 2007. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. *Cell*. 130:1083–1094. <http://dx.doi.org/10.1016/j.cell.2007.08.019>
- DeNardo, D.G., D.J. Brennan, E. Rexhepaj, B. Ruffell, S.L. Shiao, S.F. Madden, W.M. Gallagher, N. Wadhvani, S.D. Keil, S.A. Junaid, et al. 2011. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. *Cancer Discov*. 1:54–67. <http://dx.doi.org/10.1158/2159-8274.CD-10-0028>
- Dijkgraaf, E.M., M. Heusinkveld, B. Tummers, L.T. Vogelpoel, R. Goedemans, V. Jha, J.W. Nortier, M.J. Welters, J.R. Kroep, and S.H. van der Burg. 2013. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. *Cancer Res*. 73:2480–2492. <http://dx.doi.org/10.1158/0008-5472.CAN-12-3542>
- Durante, M., N. Reppingen, and K.D. Held. 2013. Immunologically augmented cancer treatment using modern radiotherapy. *Trends Mol. Med.* 19:565–582. <http://dx.doi.org/10.1016/j.molmed.2013.05.007>
- Escobar, G., D. Moi, A. Ranghetti, P. Ozkal-Baydin, M.L. Squadrito, A. Kajaste-Rudnitski, A. Bondanza, B. Gentner, M. De Palma, R. Mazzeri, and L. Naldini. 2014. Genetic engineering of hematopoiesis for targeted IFN- α delivery inhibits breast cancer progression. *Sci. Transl. Med.* 6:217ra3. <http://dx.doi.org/10.1126/scitranslmed.3006353>
- Franklin, R.A., W. Liao, A. Sarkar, M.V. Kim, M.R. Bivona, K. Liu, E.G. Pamer, and M.O. Li. 2014. The cellular and molecular origin of tumor-associated macrophages. *Science*. 344:921–925. <http://dx.doi.org/10.1126/science.1252510>
- Furness, A.J., F.A. Vargas, K.S. Peggs, and S.A. Quezada. 2014. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. *Trends Immunol.* 35:290–298. <http://dx.doi.org/10.1016/j.it.2014.05.002>
- Gabrilovich, D.I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. *Nat. Rev. Immunol.* 12:253–268. <http://dx.doi.org/10.1038/nri3175>
- Gabrusiewicz, K., D. Liu, N. Cortes-Santiago, M.B. Hossain, C.A. Conrad, K.D. Aldape, G.N. Fuller, F.C. Marini, M.M. Alonso, M.A. Idoate,

- et al. 2014. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. *Oncotarget*. 5:2208–2220.
- Gautier, E.L., S. Ivanov, J.W. Williams, S.C. Huang, G. Marcelin, K. Fairfax, P.L. Wang, J.S. Francis, P. Leone, D.B. Wilson, et al. 2014. Gata6 regulates aspartoacylase expression in resident peritoneal macrophages and controls their survival. *J. Exp. Med.* 211:1525–1531. <http://dx.doi.org/10.1084/jem.20140570>
- Germano, G., R. Frapolli, C. Belgiovine, A. Anselmo, S. Pesce, M. Liguori, E. Erba, S. Uboldi, M. Zucchetti, F. Pasqualini, et al. 2013. Role of macrophage targeting in the antitumor activity of trabectedin. *Cancer Cell*. 23:249–262. <http://dx.doi.org/10.1016/j.ccr.2013.01.008>
- Golden, E.B., S. Demaria, P.B. Schiff, A. Chachoua, and S.C. Formenti. 2013. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. *Cancer Immunol. Res.* 1:365–372. <http://dx.doi.org/10.1158/2326-6066.CIR-13-0115>
- Golden, E.B., D. Frances, I. Pellicciotta, S. Demaria, M. Helen Barcellos-Hoff, and S.C. Formenti. 2014. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. *Oncol Immunology*. 3:e28518. <http://dx.doi.org/10.4161/onci.28518>
- Gosselin, D., V.M. Link, C.E. Romanoski, G.J. Fonseca, D.Z. Eichenfield, N.J. Spann, J.D. Stender, H.B. Chun, H. Garner, F. Geissmann, and C.K. Glass. 2014. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. *Cell*. 159:1327–1340. <http://dx.doi.org/10.1016/j.cell.2014.11.023>
- Goswami, S., E. Sahai, J.B. Wyckoff, M. Cammer, D. Cox, F.J. Pixley, E.R. Stanley, J.E. Segall, and J.S. Condeelis. 2005. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. *Cancer Res.* 65:5278–5283. <http://dx.doi.org/10.1158/0008-5472.CAN-04-1853>
- Grimaldi, A.M., E. Simeone, D. Giannarelli, P. Muto, S. Falivene, V. Borzillo, F.M. Giugliano, F. Sandomenico, A. Petrillo, M. Curvietto, et al. 2014. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. *Oncol Immunology*. 3:e28780. <http://dx.doi.org/10.4161/onci.28780>
- Hagemann, T., T. Lawrence, I. McNeish, K.A. Charles, H. Kulbe, R.G. Thompson, S.C. Robinson, and F.R. Balkwill. 2008. “Re-educating” tumor-associated macrophages by targeting NF- κ B. *J. Exp. Med.* 205:1261–1268. <http://dx.doi.org/10.1084/jem.20080108>
- Hanahan, D., and R.A. Weinberg. 2011. Hallmarks of cancer: the next generation. *Cell*. 144:646–674. <http://dx.doi.org/10.1016/j.cell.2011.02.013>
- Iida, N., A. Dzutsev, C.A. Stewart, L. Smith, N. Bouladoux, R.A. Weingarten, D.A. Molina, R. Salcedo, T. Back, S. Cramer, et al. 2013. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. *Science*. 342:967–970. <http://dx.doi.org/10.1126/science.1240527>
- Jenkins, S.J., D. Ruckerl, P.C. Cook, L.H. Jones, F.D. Finkelman, N. van Rooijen, A.S. MacDonald, and J.E. Allen. 2011. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. *Science*. 332:1284–1288. <http://dx.doi.org/10.1126/science.1204351>
- Jinushi, M., S. Chiba, H. Yoshiyama, K. Masutomi, I. Kinoshita, H. Dosaka-Akita, H. Yagita, A. Takaoka, and H. Tahara. 2011. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. *Proc. Natl. Acad. Sci. USA*. 108:12425–12430. <http://dx.doi.org/10.1073/pnas.1106645108>
- Klug, F., H. Prakash, P.E. Huber, T. Seibel, N. Bender, N. Halama, C. Pfirsche, R.H. Voss, C. Timke, L. Umansky, et al. 2013. Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. *Cancer Cell*. 24:589–602. <http://dx.doi.org/10.1016/j.ccr.2013.09.014>
- Kohyama, M., W. Ise, B.T. Edelson, P.R. Wilker, K. Hildner, C. Mejia, W.A. Frazier, T.L. Murphy, and K.M. Murphy. 2009. Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis. *Nature*. 457:318–321. <http://dx.doi.org/10.1038/nature07472>
- Krausgruber, T., K. Blazek, T. Smallie, S. Alzabin, H. Lockstone, N. Sahgal, T. Hussell, M. Feldmann, and I.A. Udalova. 2011. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. *Nat. Immunol.* 12:231–238. <http://dx.doi.org/10.1038/ni.1990>
- Kroemer, G., L. Galluzzi, O. Kepp, and L. Zitvogel. 2013. Immunogenic cell death in cancer therapy. *Annu. Rev. Immunol.* 31:51–72. <http://dx.doi.org/10.1146/annurev-immunol-032712-100008>
- Kryczek, I., L. Zou, P. Rodriguez, G. Zhu, S. Wei, P. Mottram, M. Brumlik, P. Cheng, T. Curiel, L. Myers, et al. 2006. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. *J. Exp. Med.* 203:871–881. <http://dx.doi.org/10.1084/jem.20050930>
- Laoui, D., E. Van Overmeire, G. Di Conza, C. Aldeni, J. Keirse, Y. Morias, K. Movahedi, I. Houbracken, E. Schouppe, Y. Elkrim, et al. 2014. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. *Cancer Res.* 74:24–30. <http://dx.doi.org/10.1158/0008-5472.CAN-13-1196>
- Lavin, Y., D. Winter, R. Blecher-Gonen, E. David, H. Keren-Shaul, M. Merad, S. Jung, and I. Amit. 2014. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. *Cell*. 159:1312–1326. <http://dx.doi.org/10.1016/j.cell.2014.11.018>
- Lu-Emerson, C., M. Snuderl, N.D. Kirkpatrick, J. Goveia, C. Davidson, Y. Huang, L. Riedemann, J. Taylor, P. Ivy, D.G. Duda, et al. 2013. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. *Neuro-oncol.* 15:1079–1087. <http://dx.doi.org/10.1093/neuonc/not082>
- Ma, Y., L. Galluzzi, L. Zitvogel, and G. Kroemer. 2013. Autophagy and cellular immune responses. *Immunity*. 39:211–227. <http://dx.doi.org/10.1016/j.immuni.2013.07.017>
- Makkouk, A., and G.J. Weiner. 2015. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. *Cancer Res.* 75:5–10. <http://dx.doi.org/10.1158/0008-5472.CAN-14-2538>
- Manthey, C.L., D.L. Johnson, C.R. Illig, R.W. Tuman, Z. Zhou, J.F. Baker, M.A. Chaikin, R.R. Donatelli, C.F. Franks, L. Zeng, et al. 2009. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. *Mol. Cancer Ther.* 8:3151–3161. <http://dx.doi.org/10.1158/1535-7163.MCT-09-0255>
- Mantovani, A., N. Polentarutti, W. Luini, G. Peri, and F. Spreafico. 1979. Role of host defense mechanisms in the antitumor activity of adriamycin and daunomycin in mice. *J. Natl. Cancer Inst.* 63:61–66.
- Mantovani, A., B. Bottazzi, F. Colotta, S. Sozzani, and L. Ruco. 1992. The origin and function of tumor-associated macrophages. *Immunol. Today*. 13:265–270. [http://dx.doi.org/10.1016/0167-5699\(92\)90008-U](http://dx.doi.org/10.1016/0167-5699(92)90008-U)
- Mantovani, A., P. Allavena, A. Sica, and F. Balkwill. 2008. Cancer-related inflammation. *Nature*. 454:436–444. <http://dx.doi.org/10.1038/nature07205>
- Mantovani, A., S.K. Biswas, M.R. Galdiero, A. Sica, and M. Locati. 2013. Macrophage plasticity and polarization in tissue repair and remodeling. *J. Pathol.* 229:176–185. <http://dx.doi.org/10.1002/path.4133>
- Mazzieri, R., F. Pucci, D. Moi, E. Zonari, A. Ranghetti, A. Berti, L.S. Politi, B. Gentner, J.L. Brown, L. Naldini, and M. De Palma. 2011. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. *Cancer Cell*. 19:512–526. <http://dx.doi.org/10.1016/j.ccr.2011.02.005>
- McGovern, N., A. Schlitzer, M. Gunawan, L. Jardine, A. Shin, E. Poyner, K. Green, R. Dickinson, X.N. Wang, D. Low, et al. 2014. Human dermal CD14⁺ cells are a transient population of monocyte-derived macrophages. *Immunity*. 41:465–477. <http://dx.doi.org/10.1016/j.immuni.2014.08.006>
- Mitchem, J.B., D.J. Brennan, B.L. Knolhoff, B.A. Belt, Y. Zhu, D.E. Sanford, L. Belaygorod, D. Carpenter, L. Collins, D. Piwnicka-Worms, et al. 2013. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. *Cancer Res.* 73:1128–1141. <http://dx.doi.org/10.1158/0008-5472.CAN-12-2731>

- Moding, E.J., M.B. Kastan, and D.G. Kirsch. 2013. Strategies for optimizing the response of cancer and normal tissues to radiation. *Nat. Rev. Drug Discov.* 12:526–542. <http://dx.doi.org/10.1038/nrd4003>
- Moeller, B.J., Y. Cao, C.Y. Li, and M.W. Dewhirst. 2004. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. *Cancer Cell.* 5:429–441. [http://dx.doi.org/10.1016/S1535-6108\(04\)00115-1](http://dx.doi.org/10.1016/S1535-6108(04)00115-1)
- Molawi, K., Y. Wolf, P.K. Kandalla, J. Favret, N. Hagemeyer, K. Frenzel, A.R. Pinto, K. Klapproth, S. Henri, B. Malissen, et al. 2014. Progressive replacement of embryo-derived cardiac macrophages with age. *J. Exp. Med.* 211:2151–2158. <http://dx.doi.org/10.1084/jem.20140639>
- Mosser, D.M., and J.P. Edwards. 2008. Exploring the full spectrum of macrophage activation. *Nat. Rev. Immunol.* 8:958–969. <http://dx.doi.org/10.1038/nri2448>
- Movahedi, K., D. Laoui, C. Gysemans, M. Baeten, G. Stangé, J. Van den Bossche, M. Mack, D. Pipeleers, P. In't Veld, P. De Baetselier, and J.A. Van Ginderachter. 2010. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. *Cancer Res.* 70:5728–5739. <http://dx.doi.org/10.1158/0008-5472.CAN-09-4672>
- Murray, P.J., J.E. Allen, S.K. Biswas, E.A. Fisher, D.W. Gilroy, S. Goerd, S. Gordon, J.A. Hamilton, L.B. Ivashkiv, T. Lawrence, et al. 2014. Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity.* 41:14–20. <http://dx.doi.org/10.1016/j.immuni.2014.06.008>
- Noy, R., and J.W. Pollard. 2014. Tumor-associated macrophages: from mechanisms to therapy. *Immunity.* 41:49–61. <http://dx.doi.org/10.1016/j.immuni.2014.06.010>
- Okabe, Y., and R. Medzhitov. 2014. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. *Cell.* 157:832–844. <http://dx.doi.org/10.1016/j.cell.2014.04.016>
- Ostuni, R., V. Piccolo, I. Barozzi, S. Polletti, A. Termanini, S. Bonifacio, A. Curina, E. Prosperini, S. Ghisletti, and G. Natoli. 2013. Latent enhancers activated by stimulation in differentiated cells. *Cell.* 152:157–171. <http://dx.doi.org/10.1016/j.cell.2012.12.018>
- Pallasch, C.P., I. Leskov, C.J. Braun, D. Vorholt, A. Drake, Y.M. Soto-Feliciano, E.H. Bent, J. Schwamb, B. Iliopoulou, N. Kutsch, et al. 2014. Sensitizing protective tumor microenvironments to antibody-mediated therapy. *Cell.* 156:590–602. <http://dx.doi.org/10.1016/j.cell.2013.12.041>
- Pardoll, D.M. 2012. The blockade of immune checkpoints in cancer immunotherapy. *Nat. Rev. Cancer.* 12:252–264. <http://dx.doi.org/10.1038/nrc3239>
- Paulus, P., E.R. Stanley, R. Schäfer, D. Abraham, and S. Aharinejad. 2006. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. *Cancer Res.* 66:4349–4356. <http://dx.doi.org/10.1158/0008-5472.CAN-05-3523>
- Pienta, K.J., J.P. Machiels, D. Schrijvers, B. Alekseev, M. Shkolnik, S.J. Crabb, S. Li, S. Seetharam, T.A. Puchalski, C. Takimoto, et al. 2013. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. *Invest. New Drugs.* 31:760–768. <http://dx.doi.org/10.1007/s10637-012-9869-8>
- Postow, M.A., M.K. Callahan, C.A. Barker, Y. Yamada, J. Yuan, S. Kitano, Z. Mu, T. Rasalan, M. Adamow, E. Ritter, et al. 2012. Immunologic correlates of the abscopal effect in a patient with melanoma. *N. Engl. J. Med.* 366:925–931. <http://dx.doi.org/10.1056/NEJMoa1112824>
- Priceman, S.J., J.L. Sung, Z. Shaposhnik, J.B. Burton, A.X. Torres-Collado, D.L. Moughon, M. Johnson, A.J. Lusic, D.A. Cohen, M.L. Iruela-Arispe, and L. Wu. 2010. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. *Blood.* 115:1461–1471. <http://dx.doi.org/10.1182/blood-2009-08-237412>
- Pujade-Lauraine, E., J.P. Guastalla, N. Colombo, P. Devillier, E. François, P. Fumoleau, A. Monnier, M. Nooy, L. Mignot, R. Bugat, et al. 1996. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. *J. Clin. Oncol.* 14:343–350.
- Pyonteck, S.M., L. Akkari, A.J. Schuhmacher, R.L. Bowman, L. Sevenich, D.F. Quail, O.C. Olson, M.L. Quick, J.T. Huse, V. Teijeiro, et al. 2013. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. *Nat. Med.* 19:1264–1272. <http://dx.doi.org/10.1038/nm.3337>
- Ries, C.H., M.A. Cannarile, S. Hoves, J. Benz, K. Wartha, V. Runza, F. Rey-Giraud, L.P. Pradel, F. Feuerhake, I. Klamann, et al. 2014. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. *Cancer Cell.* 25:846–859. <http://dx.doi.org/10.1016/j.ccr.2014.05.016>
- Rolny, C., M. Mazzone, S. Tugues, D. Laoui, I. Johansson, C. Coulon, M.L. Squadrito, I. Segura, X. Li, E. Knevels, et al. 2011. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. *Cancer Cell.* 19:31–44. <http://dx.doi.org/10.1016/j.ccr.2010.11.009>
- Rosas, M., L.C. Davies, P.J. Giles, C.T. Liao, B. Kharfan, T.C. Stone, V.B. O'Donnell, D.J. Fraser, S.A. Jones, and P.R. Taylor. 2014. The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal. *Science.* 344:645–648. <http://dx.doi.org/10.1126/science.1251414>
- Ruffell, B., N.I. Affara, and L.M. Coussens. 2012. Differential macrophage programming in the tumor microenvironment. *Trends Immunol.* 33:119–126. <http://dx.doi.org/10.1016/j.it.2011.12.001>
- Ruffell, B., D. Chang-Strachan, V. Chan, A. Rosenbusch, C.M. Ho, N. Pryer, D. Daniel, E.S. Hwang, H.S. Rugo, and L.M. Coussens. 2014. Macrophage IL-10 blocks CD8⁺ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. *Cancer Cell.* 26:623–637. <http://dx.doi.org/10.1016/j.ccell.2014.09.006>
- Russell, J.S., and J.M. Brown. 2013. The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. *Front. Physiol.* 4:157. <http://dx.doi.org/10.3389/fphys.2013.00157>
- Sandhu, S.K., K. Papadopoulos, P.C. Fong, A. Patnaik, C. Messiou, D. Olmos, G. Wang, B.J. Tromp, T.A. Puchalski, F. Balkwill, et al. 2013. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. *Cancer Chemother. Pharmacol.* 71:1041–1050. <http://dx.doi.org/10.1007/s00280-013-2099-8>
- Selby, M.J., J.J. Engelhardt, M. Quigley, K.A. Henning, T. Chen, M. Srinivasan, and A.J. Korman. 2013. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. *Cancer Immunol Res.* 1:32–42. <http://dx.doi.org/10.1158/2326-6066.CIR-13-0013>
- Shand, F.H., S. Ueha, M. Otsuji, S.S. Koid, S. Shichino, T. Tsukui, M. Kosugi-Kanaya, J. Abe, M. Tomura, J. Ziogas, and K. Matsushima. 2014. Tracking of intertissue migration reveals the origins of tumor-infiltrating monocytes. *Proc. Natl. Acad. Sci. USA.* 111:7771–7776. <http://dx.doi.org/10.1073/pnas.1402914111>
- Shiao, S.L., and L.M. Coussens. 2010. The tumor-immune microenvironment and response to radiation therapy. *J. Mammary Gland Biol. Neoplasia.* 15:411–421. <http://dx.doi.org/10.1007/s10911-010-9194-9>
- Shree, T., O.C. Olson, B.T. Elie, J.C. Kester, A.L. Garfall, K. Simpson, K.M. Bell-McGuinn, E.C. Zabor, E. Brogi, and J.A. Joyce. 2011. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. *Genes Dev.* 25:2465–2479. <http://dx.doi.org/10.1101/gad.180331.111>
- Sica, A., and A. Mantovani. 2012. Macrophage plasticity and polarization: in vivo veritas. *J. Clin. Invest.* 122:787–795. <http://dx.doi.org/10.1172/JCI59643>
- Simpson, T.R., F. Li, W. Montalvo-Ortiz, M.A. Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J.Y. Henry, H. Yagita, J.D. Wolchok, et al. 2013. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. *J. Exp. Med.* 210:1695–1710. <http://dx.doi.org/10.1084/jem.20130579>
- Sliwkowski, M.X., and I. Mellman. 2013. Antibody therapeutics in cancer. *Science.* 341:1192–1198. <http://dx.doi.org/10.1126/science.1241145>
- Sprinzl, M.F., F. Reisinger, A. Puschnik, M. Ringelhan, K. Ackermann, D. Hartmann, M. Schiemann, A. Weinmann, P.R. Galle, M. Schuchmann, et al. 2013. Sorafenib perpetuates cellular anticancer effector functions

- by modulating the crosstalk between macrophages and natural killer cells. *Hepatology*. 57:2358–2368. <http://dx.doi.org/10.1002/hep.26328>
- Srivastava, K., J. Hu, C. Korn, S. Savant, M. Teichert, S.S. Kapel, M. Jugold, E. Besemfelder, M. Thomas, M. Pasparakis, and H.G. Augustin. 2014. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. *Cancer Cell*. 26:880–895. <http://dx.doi.org/10.1016/j.ccell.2014.11.005>
- Tymozuk, P., H. Evens, V. Marzola, K. Wachowicz, M.H. Wasmer, S. Datta, E. Müller-Holzner, H. Fiegl, G. Böck, N. van Rooijen, et al. 2014. In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors. *Eur. J. Immunol*. 44:2247–2262. <http://dx.doi.org/10.1002/eji.201344304>
- Viaud, S., F. Saccheri, G. Mignot, T. Yamazaki, R. Daillère, D. Hannani, D.P. Enot, C. Pfirschke, C. Engblom, M.J. Pittet, et al. 2013. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. *Science*. 342:971–976. <http://dx.doi.org/10.1126/science.1240537>
- Weitzenfeld, P., and A. Ben-Baruch. 2014. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. *Cancer Lett*. 352:36–53. <http://dx.doi.org/10.1016/j.canlet.2013.10.006>
- Weizman, N., Y. Krelin, A. Shabtay-Orbach, M. Amit, Y. Binenbaum, R.J. Wong, and Z. Gil. 2014. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. *Oncogene*. 33:3812–3819. <http://dx.doi.org/10.1038/onc.2013.357>
- Wynn, T.A., A. Chawla, and J.W. Pollard. 2013. Macrophage biology in development, homeostasis and disease. *Nature*. 496:445–455. <http://dx.doi.org/10.1038/nature12034>
- Xu, J., J. Escamilla, S. Mok, J. David, S. Priceman, B. West, G. Bollag, W. McBride, and L. Wu. 2013. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. *Cancer Res*. 73:2782–2794. <http://dx.doi.org/10.1158/0008-5472.CAN-12-3981>
- Zeisberger, S.M., B. Odermatt, C. Marty, A.H. Zehnder-Fjällman, K. Ballmer-Hofer, and R.A. Schwendener. 2006. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. *Br. J. Cancer*. 95:272–281. <http://dx.doi.org/10.1038/sj.bjc.6603240>
- Zhang, C.C., Z. Yan, Q. Zhang, K. Kuszpit, K. Zasadny, M. Qiu, C.L. Painter, A. Wong, E. Kraynov, M.E. Arango, et al. 2010. PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity. *Clin. Cancer Res*. 16:5177–5188. <http://dx.doi.org/10.1158/1078-0432.CCR-10-1343>